Scope of existing collaboration to include lymphomas and Kite exercises option to Arcellx’s ARC-SparX program ACLX-001 in multiple myeloma. Arcellx, Inc. and Kite, a Gilead Company, have expanded the scope of their existing collaboration for CART-ddBCMA to...
Novartis will give a solid-tumor-focused cell therapy the T-Charge treatment, after paying $100 million upfront to Legend Biotech for a selection of CAR-T candidates. The therapies in question all target Delta-like ligand protein 3 (DLL3), including an autologous...
Kite, the Gilead subsidiary specializing in CAR-T, is trying out epigenetic editing as it seeks new ways to create next-generation cell therapies that are more effective against cancer. Teaming up with California-based Epic Bio, Kite will tap its new partner’s...
If it wasn’t enough for Cargo Therapeutics to raise $200 million and recruit a C-suite of biopharma veterans so far this year, the CAR-T-focused company is now eying up an IPO. Despite launching in 2021, the San Mateo, California-based biotech only came into view this...
Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) is currently developing a genetic approach to regulating NR2F6 levels in human T cells. The Company has recently received unexpected and potentially extremely useful data from one of its contract research...
